XOMA (NASDAQ:XOMA) Upgraded by TheStreet to C

TheStreet upgraded shares of XOMA (NASDAQ:XOMA) from a d+ rating to a c rating in a research report report published on Tuesday, TheStreetRatingsTable reports.

A number of other analysts also recently commented on XOMA. HC Wainwright set a $30.00 price target on XOMA and gave the company a buy rating in a research report on Friday, September 27th. ValuEngine raised XOMA from a strong sell rating to a sell rating in a research report on Wednesday, November 6th. Zacks Investment Research raised XOMA from a hold rating to a buy rating and set a $24.00 target price for the company in a research report on Saturday, November 9th. Finally, Wedbush reissued a buy rating and issued a $25.00 target price on shares of XOMA in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating and three have issued a buy rating to the company’s stock. XOMA currently has an average rating of Buy and a consensus target price of $26.33.

Shares of XOMA stock traded up $0.38 on Tuesday, hitting $25.28. 54,500 shares of the company’s stock traded hands, compared to its average volume of 48,513. The company has a debt-to-equity ratio of 1.31, a current ratio of 4.37 and a quick ratio of 4.37. The company has a market capitalization of $215.74 million, a price-to-earnings ratio of -15.90 and a beta of 1.26. The company has a fifty day moving average of $19.68 and a two-hundred day moving average of $17.72. XOMA has a one year low of $11.02 and a one year high of $25.29.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.68. The company had revenue of $8.86 million during the quarter. XOMA had a negative return on equity of 8.93% and a negative net margin of 10.19%. Equities research analysts anticipate that XOMA will post -0.22 earnings per share for the current year.

In other XOMA news, CFO Thomas M. Burns sold 3,829 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $21.96, for a total value of $84,084.84. Following the completion of the sale, the chief financial officer now directly owns 10,384 shares of the company’s stock, valued at $228,032.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James R. Neal sold 4,348 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $22.00, for a total value of $95,656.00. Following the completion of the sale, the chief executive officer now directly owns 22,017 shares of the company’s stock, valued at $484,374. The disclosure for this sale can be found here. Insiders sold 17,459 shares of company stock valued at $374,142 over the last three months. Company insiders own 9.89% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC increased its position in XOMA by 18.9% in the second quarter. Stonepine Capital Management LLC now owns 270,449 shares of the biotechnology company’s stock worth $4,019,000 after buying an additional 43,019 shares during the last quarter. RBF Capital LLC bought a new position in shares of XOMA in the second quarter worth $1,479,000. Paloma Partners Management Co bought a new position in shares of XOMA in the second quarter worth $510,000. Marshall Wace LLP bought a new position in shares of XOMA in the second quarter worth $434,000. Finally, Morgan Stanley boosted its holdings in shares of XOMA by 2,151.6% in the second quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock worth $355,000 after acquiring an additional 22,828 shares during the period. 44.48% of the stock is owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Featured Article: Growth Stocks

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.